Cargando…

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

BACKGROUND: Guselkumab is a selective interleukin (IL)-23 inhibitor targeting the IL-23p19 subunit. In the phase 3b COSMOS trial, guselkumab demonstrated efficacy in treating participants with active psoriatic arthritis (PsA) and inadequate response (IR; lack of efficacy or intolerance) to tumor nec...

Descripción completa

Detalles Bibliográficos
Autores principales: Schett, Georg, Chen, Warner, Gao, Sheng, Chakravarty, Soumya D., Shawi, May, Lavie, Frederic, Zimmermann, Miriam, Sharaf, Mohamed, Coates, Laura C., Siebert, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428525/
https://www.ncbi.nlm.nih.gov/pubmed/37587493
http://dx.doi.org/10.1186/s13075-023-03125-4